TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Percentage of subjects with absence of ULS containing medium-grade intraepithelial neoplasia (MGIN) or high-grade intraepithelial neoplasia (HGIN) within the original TA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Survival (lack of implant component removal or revision)
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of subjects with Grade III or IV mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of PICC-related infections
Endpoint domain: Adverse events/effects
Primary endpoint: Visual analog scale (VAS) rating of pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Efficacy assessment of either cured or improved
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Mean aortic gradient after device implantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of patients with infections
Endpoint domain: Adverse events/effects
Primary endpoint: PD-L1 status of the tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: In hospital morbidity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of the ColdZyme barrier
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed-Up-and-Go (TUG) duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NeuroTrax Executive Function score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Sensitivity and Specificity of PET brain imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-operative Quality of Recovery Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: mRNA expression of L-plastin, lipocalin and adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completing program content
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Inhibition platelet activity index (ADP induced aggregation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Verbal working memory function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: BMI percentile at 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral muscle oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of acute lower respiratory infection (pneumonia)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Liver toxicity assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Lower Quarter Y-Balance Test (YBT-LQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cervical dilatation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Serum Trough Concentration (C-trough) of Golimumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bayesian Area Under Curve at Steady State (AUCss)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal tolerated dose or maximal administered dose
Endpoint domain: Adverse events/effects
Primary endpoint: Primary Parkinsonian Pain Questionnaire (3PDQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in weekly mean of 24 hour average pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cutaneous silent period latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: cutaneous silent period duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Patients Who Did Not Experience an Inappropriate Shock
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With a Serological Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the gut microbiome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of Cesarean Section
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: DNA gains and losses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: RNA expression in tumor samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mutations in candidate tumor-suppressor genes and oncogenes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Eating Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morbidity rate of complications after trauma
Endpoint domain: Adverse events/effects
Primary endpoint: Structural connectivity of the thalamo-cortical network
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cardiac energy performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Median frequency of electromyography
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: SCD-specific Knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of patients suffering from arrhythmias
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diagnostic quality of low dose CT images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 30 day complications
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titer (GMT) of Serum Anti-hemagglutinin (HA) Antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects Who Seroconverted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in ASC mRNA Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pro-inflammatory and Anti-inflammatory Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Astrand-rhyming Submaximal Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participants With a Clinical Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Change of Tumor Burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Time to Next Treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: NK cell killing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ADOS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improved parent experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of Patients With Grade II-IV Acute GvHD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GBS Culture Result
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in quality of life (including fatigue and sleep disturbances)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: PMDD symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Range of motion (ROM) of the neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Roland-Morris Disability Questionnaire (RDQ)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: change of hospitalization rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percentage of Participants Attaining a Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Attaining a Partial Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Timed Up and Go-test (TUG) in seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: worsening heart failure requiring hospitalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: increase in diuretic dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diabetes Self-efficacy Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in AUC0-8 of Aldesleukin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ACR20 response at week 24
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Efficacy of Tocilizumab on BD Uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of lower urinary tract symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction of psychosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of obsessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic effect measured by CDAI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Therapeutic effect measured by enteroscope
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: micro nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion Of Participants With A Clinical Outcome Of Cure, Improved, Or Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Infection-related Length Of Stay For Infections Being Treated With Minocycline IV
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number Of Participants With A Microbiologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area Under the Concentration Versus Time Curve (AUC[0-24])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of lenalidomide in combination with fludarabine-rituximab
Endpoint domain: Adverse events/effects
Primary endpoint: Value of Procalcitonin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Value of C-Reactive Protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Value of Neutrophyl to Lymphocyte Ratio (NLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of epidural morphine/ropivacaine treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate after 3 cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate after 6 cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean of the progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of Participants With a Vaccine-Related Serious Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titer (GMT) Ratio of Pneumococcal Serotype-specific Opsonophagocytic Activity (OPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: GMT of Influenza Strain-Specific Hemagglutination Inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Preoperative Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Postoperative Pain Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SIRS at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to Peak Concentration (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Area Under the Concentration-time Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Pathological response rate (ypRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Adverse Events related to toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of MALE
Endpoint domain: Mortality/survival
Primary endpoint: Changing mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Change of patient perception of bladder condition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Social brain network properties
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain response pattern for oxytocin concepts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of patients with major cytogenetic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area Under the Curve (AUC 0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improvement in urine leakage volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: QTcLD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: WOOS (Western Ontario Osteoarthritis of the Shoulder) Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: pAMPKThr172 in skeletal muscle tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pERK 1/2Thr202/Tyr204 in skeletal muscle tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: IGF-1 mRNA in skeletal muscle tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Socioeconomic burden to households
Endpoint domain: Resource use
Endpoint subdomain: Societal/carer burden
Primary endpoint: Maximum Papillae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Maximum Eyelid Hyperaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Upper Lid Redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change From Baseline in Upper Eyelid Margin Staining at Month 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Changes of cardiopulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of non progression at the end of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients for whom at least one of the 3 defined tolerance criteria is observed
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With One or More Drug-Related Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of psychiatric symptoms in COVID-19 ICU survivors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of psychiatric symptoms among relatives of COVID-19 ICU survivors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ACR20 Response at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Postprandial oxidative stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial plasma concentrations of gastrointestinal peptides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: first episode of culture-confirmed influenza illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Standardized uptake value of 68Ga-NOTA-RM26 in breast tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: time needed to fall asleep
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical Indicators of Vitamin D and calcium status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Internal rotation deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Frequency of prenatal care attendance and syphilis screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean Annual Rate of Moderate or Severe COPD Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Degree of fecal matter and residual liquid production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Anti HIV false positivity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in FEV1 AUC0-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Presence of antibodies to HIV antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Immune Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With ≥1 New Vertebral Fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants Who Received At Least 1 Infusion of Sipuleucel-T
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction in pain severity based on VAS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consumption of postoperative pain medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of Neuropathic pain Syndromes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient daily activity and functional capacity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Effect on phases I-III of the migrating motor complex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Production of RNA PMP22
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Immunoglobulin measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of rescue analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of stroke or transient ischemic attack
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in estimated glomerular filtration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Time of care in the adult emergency department
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Stimulated pain intensity measure (P5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Calcitonin gene-related peptide (CGRP) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tear fluid production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality and hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Change in self-care
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Protein and mRNA expression of pro- and contra-inflammatory factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Plasma IGF-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma IGFBP-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Normalized Mean Tremor Amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Energy expenditure/metabolism during physical stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Subjective arousal/stress/fatigue ratings during physical stress
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Recovery biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SUVmax of positive lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients received the entire treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Fecal Characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Intestinal microflora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Evidence of pancreatic fistula
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change From Baseline in Patient Global Assessment of Osteoarthritis Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Improvement or worsening of IBS global symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in severity of IBS symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes